At a glance
BioLife Solutions Inc is worth $1.89B. Revenue grew 28.9% to $96.2M in fiscal 2025, at a loss; over 3 years it has grown 8.1% a year. It pays no dividend. The stock returned +38.0% over the past year with dividends reinvested and −5.3% a year over five years, against +11.5% and +11.7% for the S&P 500. At its worst it fell 48.8% in the 2020 crash (S&P 500: 33.7%) and 71.7% in the 2022 bear market (S&P 500: 24.5%), and was back at its earlier high 2 months and 52 months after the lows.
The business in plain English
BioLife Solutions makes products that keep living cells healthy while they are collected, processed, frozen, shipped and thawed. Its customers mainly develop and make cell and gene therapies, which are treatments built from living cells or genetic material. Its core products are CryoStor freeze media and HypoThermosol FRS. These are solutions that protect cells from damage when they are chilled or frozen. Customers have referenced BioLife's FDA product file more than 750 times in their own filings. The company believes its products are used in several hundred active clinical trials.
BioLife reports one business with one revenue line. Besides its preservation media, it sells human platelet lysate, an ingredient for growing cells. It also sells CellSeal and CryoCase containers, automated cell-processing fill machines and ThawSTAR automated thawing devices. CryoStor products brought in about 82% of revenue in the year ended December 31, 2025. Total revenue that year was $96.2 million, up 28.9%.
BioLife has narrowed its focus. From April 2024 to October 2025 it agreed to the sale of four units: Global Cooling (ultra-low temperature freezers), SciSafe (storage and cold chain logistics), Custom Biogenic Systems (liquid nitrogen freezers) and SAVSU (evo smart shipping containers). In April 2025 it bought the remaining 90% of PanTHERA CryoSolutions. That deal added a patented technology meant to limit ice-crystal damage to frozen cells, which has yet to prove commercially viable.
Price history
The interactive chart needs JavaScript.
BLFS +38.0% over the year to Oct 28, 2026, total return with dividends reinvested.
Latest results
- In Q2 FY2026 (ended Jun 30, 2026), revenue was $28.5M, up 21.5% from a year earlier, and net income was $45.1M.
- For fiscal 2025, revenue was $96.2M (+28.9% year over year; +8.1% a year from FY2022 to FY2025) with a -4.8% net margin.
Financial health check
| Revenue growth a year (FY2022–FY2025) | +8.1% good |
|---|---|
| Operating margin | -17.3% weak |
| Free cash flow margin | 11.1% good |
| Return on equity (FY2025) | -1.2% weak |
| Return on assets (FY2025) | -1.1% weak |
| Net cash (cash minus debt) | $82.4M good |
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2020 | $48.1M | $2.0M | $4.7M |
| FY2021 | $119.2M | $-8.9M | $-13.0M |
| FY2022 | $76.2M | $-139.8M | $-18.9M |
| FY2023 | $68.0M | $-68.0M | $-18.9M |
| FY2024 | $74.6M | $-20.2M | $5.2M |
| FY2025 | $96.2M | $-4.6M | $10.6M |
Valuation snapshot
| Market value | $1.89B |
|---|---|
| P/E ratio | — |
| Dividend yield | None |
Rank among 1514 US companies
Market value at each year end
BioLife Solutions’s market value went from $20.7M at the end of 2016 to $1.89B on Oct 28, 2026, about 91.1 times as much; since the end of 2025 it is up 62%.
Show as a table
| Year end | Market value | Change |
|---|---|---|
| Oct 28, 2026 | $1.89B | +62.2% |
| 2025 | $1.16B | -3.3% |
| 2024 | $1.20B | +68.3% |
| 2023 | $715.5M | -8.1% |
| 2022 | $778.3M | -49.9% |
| 2021 | $1.55B | +18.9% |
| 2020 | $1.31B | +294.6% |
| 2019 | $330.9M | +48.7% |
| 2018 | $222.6M | +172.1% |
| 2017 | $81.8M | +294.4% |
| 2016 | $20.7M |
Price behavior
| YTD | 1 yr | 3 yr | 5 yr | 10 yr | |
|---|---|---|---|---|---|
| BLFS price data to Oct 28, 2026 | +59.7% | +38.0% | +60.5% | -5.3% | +37.2% |
Show as a table
| Year | Price data |
|---|---|
| 2026 (to date) | +59.7% |
| 2025 | -6.9% |
| 2024 | +59.8% |
| 2023 | -10.7% |
| 2022 | -51.2% |
| 2021 | -6.6% |
| 2020 | +146.5% |
| 2019 | +34.5% |
| 2018 | +100.5% |
| 2017 | +272.6% |
| 2016 | -25.8% |
| 2015 | +32.3% |
| 2014 | -80.9% |
| 2013 | +76.5% |
| 2012 | +580.0% |
| 2011 | -16.7% |
| 2010 | -45.5% |
| 2009 | +266.7% |
| 2008 | -50.0% |
| 2007 | -14.3% |
| 2006 | -41.7% |
| 2008 financial crisis stocks fell Oct 9, 2007 – Mar 9, 2009 | Lost 54.5% over that stretch · deepest drop along the way 81.8%, back to its old high 3.6 months after the low |
|---|---|
| 2020 COVID crash stocks fell Feb 19, 2020 – Mar 23, 2020 | Lost 46.4% over that stretch · deepest drop along the way 48.8%, back to its old high 2.1 months after the low |
| 2022 bear market stocks fell Jan 3, 2022 – Oct 12, 2022 | Lost 44.7% over that stretch · deepest drop along the way 71.7%, back to its old high 52.4 months after the low |
Insider activity
Form 4 filings from 2025-10-29 to 2026-10-29 (25 read): 0 open-market purchases and 0 sales ($0.00).
Who owns it
Large shareholders (13G filings)
| BlackRock, Inc. | 13.4% | Sep 30, 2026 |
| Casdin Capital, LLC | 9.7% | Jun 4, 2026 |
| T. Rowe Price Investment Management, Inc. | 7.5% | Aug 31, 2026 |
| Glazer Capital, LLC | 5.49% | Sep 17, 2026 |
| Invesco Ltd. | 4.9% | Mar 31, 2026 |
ETFs with the most weight in BLFS
| GSC Goldman Sachs Small Cap Core Equity ETF | 0.75% |
| RZG Invesco S&P SmallCap 600® Pure Growth ETF | 0.66% |
| MMSC First Trust Multi-Manager Small Cap Opportunities ETF | 0.44% |
| DWAS Invesco Dorsey Wright SmallCap Momentum ETF | 0.35% |
| IWC iShares Micro-Cap ETF | 0.24% |
| AFSM First Trust Active Factor Small Cap ETF | 0.21% |
| SLYG SPDR S&P 600 Small Cap Growth ETF | 0.14% |
| VIOG Vanguard S&P Small-Cap 600 Growth ETF | 0.13% |
What could go wrong
- Most sales come from one product line. CryoStor freeze media made up about 82% of revenue in the year ended December 31, 2025. A quality problem, a stronger rival product or weaker demand for it would hit sales hard.
- A few big customers matter a lot. Three customers supplied about 29% of revenue in the year ended December 31, 2025. Their orders swing with demand for their own therapies, and losing one could cut sales sharply.
- A product failure could damage trust. Its customers are likely to be especially sensitive to defects. If BioLife's products, or similar products from competitors, fail or are seen to fail, it could lose sales, face legal claims and harm its reputation.
- Deals reshaping the company carry risk. Between April 2024 and October 2025, BioLife agreed to the sale of four businesses. It also bought PanTHERA, whose freezing technology has yet to prove commercially viable. Deals like these may not deliver expected benefits.
- Bigger rivals with deeper pockets. Many competitors are much larger and have more money for research, marketing and distribution. They could develop better or cheaper products, and fast-moving technology could make BioLife's products obsolete.
- Depends on single-source suppliers. BioLife depends on outside suppliers and manufacturers, and some are the only source for a material or part. A supply disruption or manufacturing problem could raise costs and delay deliveries to customers.
Recent events
- Acquisition or sale of assets completed; Listing notice from the exchange; Change to shareholder rights; Change in control; Executive or board change; Bylaws or fiscal year changed; Shareholder vote results
- Other company announcement
- Quarterly results released
- Investor presentation or announcement
- Major agreement signed; Investor presentation or announcement
- Investor presentation or announcement
- Quarterly results released
- Investor presentation or announcement
- Quarterly results released
- Quarterly results released
For income and retirement investors
BioLife Solutions pays no dividend. It has never paid one on its common stock and does not expect to in the foreseeable future. It spent nothing on share buybacks from fiscal 2021 through fiscal 2025. Meanwhile the share count grew about 20%, from 40.7 million in August 2021 to 48.9 million in July 2026, thinning each owner's stake. For an income investor, that means no cash payouts; any return depends on the share price. That price has swung hard. It fell about 82% in the 2008 financial crisis and 49% in the 2020 COVID crash, recovering within a few months of the low each time. After a 72% drop in the 2022 bear market, it took until September 22, 2026 to regain its January 2022 high. Filings dated October 6, 2026 report a change in control and a listing notice from the exchange, so the shares may no longer trade. Single stocks carry more risk than diversified funds.
Questions investors ask
How does BioLife Solutions make money?
BioLife sells products that keep living cells healthy during cell and gene therapy research and manufacturing. Its main earner is biopreservation media, solutions that protect cells when chilled or frozen. CryoStor products made up about 82% of revenue in the year ended December 31, 2025. It also sells cell-growth media, containers, automated fill machines and ThawSTAR thawing devices. Revenue was $96.2 million that year. Gross margin was 64.6%, meaning about 65 cents of each sales dollar remained after direct production costs.
Does BioLife Solutions pay a dividend?
No. BioLife Solutions has never paid a dividend on its common stock. Its annual report for the year ended December 31, 2025 says it does not expect to pay one in the foreseeable future. It also spent nothing on share buybacks from fiscal 2021 through fiscal 2025, and the share count rose about 20% between August 2021 and July 2026. Any return for shareholders has to come from the share price.
Is BioLife Solutions profitable?
Not for its latest full fiscal year. BioLife lost $4.6 million in the year ended December 31, 2025, down from a $139.8 million loss in fiscal 2022. Its operating loss was $16.6 million. It did produce $10.6 million of free cash flow, which is the cash left after running the business and paying for equipment. In the quarter ended June 30, 2026, it reported net income of $45.1 million. That was more than the quarter's $28.5 million of revenue, so ordinary sales alone could not explain it.
How has BioLife Solutions stock performed?
Unevenly, with big swings. As of October 28, 2026, the share price was up about 38% over one year and about 313% over three years. It was down about 24% over five years and up roughly 2,269% in total over ten years. Along the way it fell about 72% in the 2022 bear market. Its worst drop on record was about 93%. These are price returns only, since the company pays no dividend.
Is BioLife Solutions still publicly traded?
It appears not. On October 6, 2026, BioLife filed a report covering a completed acquisition or sale of assets, a change in control, a listing notice from its stock exchange and changes to shareholder rights. SEC records also no longer show a ticker symbol for the company. That mix of filings usually comes with a completed takeover and the end of exchange trading. The October 6, 2026 filing holds the details, including who controls the company and any terms for shareholders.